Interestingly, mutation of FLT3, one of the most commonly mutated genes in AML leading to constitutive activation of its tyrosine kinase activity and subsequent activation of PI3K/RAS/STAT, correlates with low sensitivity to MDM2 inhibition and is a predictive marker of response [87]. This evidence concerns the gene MDM2 and acute myeloid leukemia.